Market Place
Sourcing Support
Neuraptive Therapeutics Announces Phase 2 Interim Results
19 Sep 2024 //
BUSINESSWIRE
Neuraptive Announces Positive 24-Week Data for NTX-001 in the Phase 2 Study
22 Feb 2024 //
BUSINESSWIRE
Neuraptive Receives Orphan Drug Designation for its Lead Development Asset
15 Jan 2024 //
BUSINESSWIRE
Neuraptive Announces Achievement of Proof of Concept in The Study of NTX-001
08 Jan 2024 //
BUSINESSWIRE
Neuraptive Strengthens its Board of Directors With Appointment of Cary Sucoff
27 Feb 2023 //
BUSINESSWIRE
Neuraptive Therapeutics Appoints Robert R. Ruffolo as New Director to the Board
17 Nov 2022 //
BUSINESSWIRE
Neuraptive Appoints Dr. Robert R. Ruffolo as New Director to the Board
17 Nov 2022 //
BUSINESSWIRE
Neuraptive Announces Organizational Updates to Support Company’s Advancements
24 Oct 2022 //
BUSINESSWIRE
Neuraptive Announces First Patient Enrolled in a Phase 2 Trial of NTX-001
21 Jul 2022 //
BUSINESSWIRE
Neuraptive Announces First Patient Enrolled in a Phase 2 Trial of NTX-001
21 Jul 2022 //
BIOSPACE
Neuraptive Announces FDA Clearance of a Second IND Application for NTX-001
13 Apr 2021 //
BUSINESSWIRE
Neuraptive Announces Activation of First Clinical Site in Ph2 Study of NTX-001
20 Oct 2020 //
BUSINESSWIRE
Neuraptive Announces Activation of First Clinical Site in Ph2 Study of NTX-001
20 Oct 2020 //
BUSINESSWIRE
Neuraptive Announces FDA has Granted Fast Track Designation to NTX-001
14 May 2020 //
BUSINESSWIRE
Neuraptive Announces FDA has Granted Fast Track Designation to NTX-001
14 May 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.